Analyzing Bicycle Therapeutics (BCYC) & The Competition

Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Bicycle Therapeutics to similar companies based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Bicycle Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicycle Therapeutics 1 4 5 0 2.40
Bicycle Therapeutics Competitors 9945 15356 45765 1601 2.54

Bicycle Therapeutics currently has a consensus price target of $13.57, suggesting a potential upside of 368.79%. As a group, “Biotechnology” companies have a potential upside of 114.65%. Given Bicycle Therapeutics’ higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than its rivals.

Volatility and Risk

Bicycle Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics’ rivals have a beta of -1.85, indicating that their average stock price is 285% less volatile than the S&P 500.

Valuation and Earnings

This table compares Bicycle Therapeutics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Bicycle Therapeutics $72.86 million -$218.96 million -1.43
Bicycle Therapeutics Competitors $688.58 million $7.69 million -17.98

Bicycle Therapeutics’ rivals have higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Bicycle Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bicycle Therapeutics -169.75% -26.02% -22.30%
Bicycle Therapeutics Competitors -12,224.75% -204.85% -31.52%

Institutional and Insider Ownership

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Bicycle Therapeutics beats its rivals on 7 of the 12 factors compared.

Bicycle Therapeutics Company Profile

(Get Free Report)

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.